News Merck partners Remepy in PDURS-focused alliance Merck KGaA has started working with Remepy on the development of hybrid drugs that combine medicines with digital therapeutics.
News Merck partners Valo on $3bn, AI-based Parkinson's project Merck has teamed up with Valo Health on a project to apply AI to the discovery of novel drug targets and drugs for Parkinson's.
News Merck joins the Trump MFN gang with IVF deal Merck KGaA has become the third drugmaker to reach a deal with the Trump administration to cut medicine costs, offering discounts on fertility drugs.
News Merck looking to rare disease deals to build health momentum Germany's Merck KGaA is looking at making further acquisitions to boost its business, with a focus on life sciences and rare diseases.
News Merck names electronics unit head to replace Garijo as CEO Merck KGaA's CEO Belén Garijo will step down next year and will be replaced by the group's electronics boss Kai Beckmann.
News Merck names new R&D chief for healthcare business Industry veteran David Weinreich will step into the top healthcare R&D role at Merck KGaA, following Danny Bar-Zohar's move to lead the division.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
